Panel: Hormone Therapy Not for Prevention of Chronic Conditions
More Risk Than Benefit When Hormone Therapy Used to Prevent Chronic Conditions
What Do the USPSTF Recommendations on HT for Prevention of Chronic Disease Mean?
Here's the exact language of the draft recommendations:
- The U.S. Preventive Services Task Force (USPSTF) recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. This is a grade D recommendation. (Discourage the use of this service.)
- The USPSTF recommends against the use of estrogen for the prevention of chronic conditions in postmenopausal women who have had a hysterectomy. This is a grade D recommendation.
- This recommendation applies to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. This recommendation does not apply to women younger than 50 who have undergone surgical menopause. This recommendation does not consider the use of hormone therapy for the management of menopausal symptoms, such as hot flashes or vaginal dryness.
The draft recommendations are posted on the USPSTF web site. Anybody who would like to post comments and/or recommend changes is welcome to do so. After considering these comments, the USPSTF will issue its final recommendations.
What will that mean?
The USPSTF is an independent panel of experts in preventive and family medicine. Members are appointed for a four-year term. Their job is to evaluate medical evidence for preventive medicine. Topics are nominated by the public and chosen by the panel.
USPSTF recommendations do not set policy, although they may serve as the basis for guidelines established by medical associations and insurers.
Under the Affordable Care Act, Medicare and health plans must pay for services recommended by the USPSTF. Medicare may pay for services not recommended by USPSTF if the Department of Health and Human Services so decides. Insurers may or may not reimburse for services not recommended by the USPSTF.
The Nelson team's review of the evidence regarding preventive use of HT appears in the May 28 issue of Annals of Internal Medicine.